Profile data is unavailable for this security.
About the company
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
- Revenue in USD (TTM)908.96m
- Net income in USD-239.70m
- Incorporated2015
- Employees2.90k
- LocationLegend Biotech Corp2101 Cottontail LaneSOMERSET 08873United StatesUSA
- Phone+1 (732) 850-5598
- Websitehttps://investors.legendbiotech.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.69bn | 483.00 | -- | 2.78 | -- | 48.31 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.71bn | 240.00 | -- | 3.46 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.73bn | 95.00 | -- | 7.10 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Immunome Inc | 9.68m | -222.74m | 2.75bn | 118.00 | -- | 8.65 | -- | 283.61 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.79bn | 143.00 | -- | 7.66 | -- | 39.44 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.82bn | 131.00 | -- | 2.58 | -- | 13.13 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.86bn | 824.00 | 95.47 | 2.27 | 54.30 | 5.78 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Disc Medicine Inc | 0.00 | -181.11m | 3.01bn | 84.00 | -- | 4.87 | -- | -- | -5.35 | -5.35 | 0.00 | 16.38 | 0.00 | -- | -- | 0.00 | -32.18 | -- | -33.75 | -- | -- | -- | -- | -- | -- | -- | 0.0481 | -- | -- | -- | -43.08 | -- | -- | -- |
| Vera Therapeutics Inc | 0.00 | -251.94m | 3.05bn | 224.00 | -- | 6.97 | -- | -- | -3.98 | -3.98 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -56.87 | -54.55 | -61.62 | -60.06 | -- | -- | -- | -- | -- | -- | 0.1576 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 3.08bn | 136.00 | -- | 5.51 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.16bn | 2.90k | -- | 3.12 | -- | 3.47 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -306.33m | 3.20bn | 316.00 | -- | 5.70 | -- | 426.35 | -3.88 | -3.88 | 0.0952 | 7.26 | 0.0104 | -- | 8.57 | 23,734.18 | -42.44 | -22.00 | -44.53 | -22.93 | -- | -- | -4,084.45 | -1,082.36 | -- | -- | 0.00 | -- | -- | -- | -28.48 | -- | 19.92 | -- |
| Viking Therapeutics Inc | 0.00 | -237.39m | 3.21bn | 50.00 | -- | 4.49 | -- | -- | -2.12 | -2.12 | 0.00 | 6.34 | 0.00 | -- | -- | 0.00 | -28.31 | -22.44 | -29.21 | -23.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -28.02 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -498.74m | 3.28bn | 517.00 | -- | 3.34 | -- | -- | -2.91 | -2.91 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -39.75 | -16.91 | -42.77 | -19.81 | -- | -- | -- | -135.24 | -- | -- | 0.006 | -- | -100.00 | -- | -191.12 | -- | -2.35 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.38bn | 233.00 | -- | 7.10 | -- | 152.96 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Legend Biotech Corp's reporting currency: US Dollar USD
29.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 24.96m | 13.52% |
| HHLR Advisors Ltd.as of 30 Sep 2025 | 6.30m | 3.41% |
| Westfield Capital Management Co. LPas of 30 Sep 2025 | 6.09m | 3.30% |
| Suvretta Capital Management LLCas of 30 Sep 2025 | 3.82m | 2.07% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 3.04m | 1.65% |
| Artisan Partners LPas of 30 Sep 2025 | 2.55m | 1.38% |
| FIAM LLCas of 30 Sep 2025 | 2.50m | 1.36% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 2.12m | 1.15% |
| Braidwell LPas of 30 Sep 2025 | 1.83m | 0.99% |
| AllianceBernstein LPas of 30 Sep 2025 | 1.63m | 0.89% |
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
